Loading...
•
Mar 31, 2021
Allogene Q1 2021 Earnings Report
Allogene Therapeutics reported financial results for the first quarter of 2021 and provided a corporate update.
Key Takeaways
Allogene Therapeutics reported a net loss of $33.0 million, or $0.25 per share, for the first quarter of 2021. The company ended the quarter with $964.2 million in cash, cash equivalents, and investments. Significant clinical and regulatory progress was made across the AlloCAR T portfolio, including the start of the first solid tumors study.
Data from the ALLO-501 ALPHA Study and ALLO-501A ALPHA2 Study to be presented at ASCO Annual Meeting.
FDA granted RMAT Designation to ALLO-715 for Relapsed/Refractory Multiple Myeloma.
Initiated Combination Arm of the UNIVERSAL Trial with ALLO-715 and Nirogacestat.
TRAVERSE Trial Initiated for ALLO-316 in Patients with Advanced or Metastatic Renal Cell Carcinoma.
Forward Guidance
Allogene continues to expect full year GAAP Operating Expenses to be between $300 million and $330 million including estimated non-cash stock-based compensation expense of $80 million to $90 million and excluding any impact from potential new business development activities.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...